Program Description
The expanding treatment landscape for renal cell carcinoma (RCC) encompasses targeted therapies, immunotherapies, and combination regimens. Treatment options following disease progression during or after immune checkpoint inhibitor (ICI) therapy are limited and continue to be a challenge in the management of metastatic RCC, but clinical trials have demonstrated that combination regimens of tyrosine kinase inhibitors (TKIs) with ICIs lead to improved overall survival and response rates in patients with metastatic RCC. Oncology pharmacists must be familiar with disease-specific factors and individual patient risk status as well as the safety and efficacy data of emerging combination ICI/TKI regimens when selecting an initial treatment. Other considerations, including treatment sequencing and awareness of severe immune-related adverse events with the use of ICI/TKI combination regimens and the oncology pharmacist’s role in ensuring patient safety will be addressed. This program will discuss essential roles of oncology pharmacists in the care of patients with metastatic RCC, such as ensuring access to available and emerging ICI/TKI combination regimens, implementing guideline recommendations, and managing toxicities.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: December 8, 2023
Expiration date: December 8, 2024
Time to complete activity: 1.0 hour
Fee: Free
Learner Level: Advanced
Educational Objectives
After completion of this activity, participants will be able to:
- Identify the pharmacology of novel agents for individualized treatment selection in patients with renal cell carcinoma (RCC)
- Compare the efficacy and safety of newly developed medications, considering their use as monotherapy or in combination for the treatment of RCC
- Optimize patient safety in RCC treatment through the application of guideline-directed toxicity monitoring and management strategies for combination regimens
Megan Hinkley, PharmD, BCOP
Clinical Specialist Pharmacist – Oncology
The James Cancer Hospital at The Ohio State University Wexner Medical Center
Columbus, Ohio
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-451-H01-P. The activity is available for CE credit through December 8, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Megan Hinkley, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Abigail Dill; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Daphne Davis, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
- Former employee: GSK
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms